Kolenda Pharmaceutical: Net profit in 2025 is 1.702 billion yuan, a year-on-year decrease of 42.03%.

Kewlen Pharmaceutical announced that the company has released its annual report for 2025, achieving operating income of 18.513 billion RMB, a year-on-year decrease of 15.13%; net profit attributable to shareholders of the listed company was 1.702 billion RMB, a year-on-year decrease of 42.03%. The company plans to distribute cash dividends of 4.68 RMB per 10 shares to all shareholders, without bonus shares or capitalizing reserves.